Suchergebnisse - "Antibodies, Monoclonal, Humanized"

PubPharm (23.217)

1

Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children

enthalten in: Expert opinion on biological therapy | 2024

von Reijman, M. | Kusters, D. | Wiegman, A.

2

Delayed drug hypersensitivity reaction to secukinumab in a patient with hidradenitis suppurativa

enthalten in: Drug and therapeutics bulletin | 2024

von Konda, S. | Shetty, N. | Friedman, B. | +1

3

Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab : Results from a Japanese claims database

enthalten in: Multiple sclerosis and related disorders | 2024

von Nakashima, I. | Nakahara, J. | Yasunaga, H. | +5

4

Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia : Pooled Data From Three Open-Label Studies

enthalten in: Arteriosclerosis, thrombosis, and vascular biology | 2024

von Raal, F. | Hegele, R. | Ruzza, A. | +8

5

Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England

enthalten in: BMC infectious diseases | 2024

von Patel, V. | Levick, B. | Boult, S. | +5

6

Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Milowsky, M. | O'Donnell, P. | Hoimes, C. | +20

7

Cost-effectiveness analysis of durvalumab, tremelimumab, and etoposide-platinum in first-line treatment of extensive-stage small cell lung cancer

enthalten in: Medicine | 2024

von Meng, M. | Liu, X. | Liang, X. | +2

8

Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir) : a retrospective cohort study

enthalten in: BMC pharmacology & toxicology | 2024

von Yalan, Q. | Lingfang, H. | Xisong, L. | +3

9

Real-world outcomes and drug survival of brodalumab : results from the German Psoriasis Registry PsoBest

enthalten in: The Journal of dermatological treatment | 2024

von Schaeffer, L. | Ben-Anaya, N. | Sorbe, C. | +3

10

Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis : A phase 2 randomized trial (CBP-201-WW001)

enthalten in: The Journal of allergy and clinical immunology | 2024

von Silverberg, J. | Strober, B. | Feinstein, B. | +13

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[2322]